Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study includ...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2411855 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846119613418438656 |
|---|---|
| author | Luigi Gargiulo Luciano Ibba Angela Alfano Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Francesca Barei Anna G. Burroni Stefano Caccavale Piergiacomo Calzavara-Pinton Maria Esposito Maria C. Fargnoli Silvia M. Ferrucci Caterina Foti Giampiero Girolomoni Massimo Gola Mario B. Guanti Carlotta Gurioli Manfredi Magliulo Martina Maurelli Pietro Morrone Maria L. Musumeci Maddalena Napolitano Michela Ortoncelli Cataldo Patruno Bianca M. Piraccini Elena Pezzolo Simone Ribero Mariateresa Rossi Paola Savoia Claudio Sciarrone Benedetta Tirone Marco Vaccino Federica Veronese Antonio Costanzo Alessandra Narcisi |
| author_facet | Luigi Gargiulo Luciano Ibba Angela Alfano Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Francesca Barei Anna G. Burroni Stefano Caccavale Piergiacomo Calzavara-Pinton Maria Esposito Maria C. Fargnoli Silvia M. Ferrucci Caterina Foti Giampiero Girolomoni Massimo Gola Mario B. Guanti Carlotta Gurioli Manfredi Magliulo Martina Maurelli Pietro Morrone Maria L. Musumeci Maddalena Napolitano Michela Ortoncelli Cataldo Patruno Bianca M. Piraccini Elena Pezzolo Simone Ribero Mariateresa Rossi Paola Savoia Claudio Sciarrone Benedetta Tirone Marco Vaccino Federica Veronese Antonio Costanzo Alessandra Narcisi |
| author_sort | Luigi Gargiulo |
| collection | DOAJ |
| description | Aim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200 mg.Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively).Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab.Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib. |
| format | Article |
| id | doaj-art-480e38bfd8864c22af37d930c2f6d234 |
| institution | Kabale University |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-480e38bfd8864c22af37d930c2f6d2342024-12-16T22:53:48ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2411855Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)Luigi Gargiulo0Luciano Ibba1Angela Alfano2Piergiorgio Malagoli3Fabrizio Amoruso4Anna Balato5Francesca Barei6Anna G. Burroni7Stefano Caccavale8Piergiacomo Calzavara-Pinton9Maria Esposito10Maria C. Fargnoli11Silvia M. Ferrucci12Caterina Foti13Giampiero Girolomoni14Massimo Gola15Mario B. Guanti16Carlotta Gurioli17Manfredi Magliulo18Martina Maurelli19Pietro Morrone20Maria L. Musumeci21Maddalena Napolitano22Michela Ortoncelli23Cataldo Patruno24Bianca M. Piraccini25Elena Pezzolo26Simone Ribero27Mariateresa Rossi28Paola Savoia29Claudio Sciarrone30Benedetta Tirone31Marco Vaccino32Federica Veronese33Antonio Costanzo34Alessandra Narcisi35Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDepartment of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, ItalyDermatology Unit, Azienda Ospedaliera di Cosenza, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, ItalyDermatology Unit, University of Campania L. Vanvitelli, Naples, ItalyDermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’ Aquila, L’ Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, University of L’ Aquila, L’ Aquila, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalySection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, ItalyDepartment of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, ItalyAllergological and Pediatric Dermatology Unit, Department of Health Sciences, University of Florence, FlorenceDepartment of Dermatology, University of Modena and Reggio Emilia, Modena, ItalyDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyAllergological and Pediatric Dermatology Unit, Department of Health Sciences, University of Florence, FlorenceDepartment of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, ItalyDermatology Unit, Azienda Ospedaliera di Cosenza, ItalyDermatology Clinic, University of Catania, Catania, ItalySection of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyDepartment of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, ItalyDermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyDepartment of Dermatology, San Bortolo Hospital, Vicenza, ItalyDepartment of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, ItalyDermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, ItalyDermatology Clinic, Department of Health Science, University of Eastern Piedmont, Novara, ItalyDepartment of Dermatology, Papardo Hospital, Messina, ItalySection of Dermatology and Venereology, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro", Bari, ItalyDermatology Clinic, University of Catania, Catania, ItalyDepartment of Dermatology, Papardo Hospital, Messina, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyDermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyAim: Abrocitinib is a JAK-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD). We conducted a 16-week multicenter retrospective study to assess the short-term effectiveness and safety of abrocitinib in patients with moderate-to-severe AD.Our retrospective study included 85 adult patients from 14 Italian Dermatology Units affected by moderate-to-severe AD treated with abrocitinib 100/200 mg.Methods: Effectiveness of abrocitinib at weeks 4 and 16 was assessed by using the Eczema Area and Severity Index (EASI), the Investigator Global Assessment (IGA), the peak pruritus and sleep- Numerical Rating Scale (PP-NRS and S-NRS, respectively).Results: At week 16, improvement of at least 90% in EASI (EASI90) and IGA 0/1 was observed in 49.4% and 61.2% of patients, respectively. A reduction of at least 4 points in PP-NRS and S-NRS compared with baseline was achieved by 70.6% of patients for both endpoints. No significant safety reports were observed during the study period. Naïve patients had better rates of EASI 90 compared to patients who previously failed dupilumab.Conclusion: Our data confirm the effectiveness of abrocitinib in a real-world setting with better clinical responses at weeks 4 and 16, compared with Phase-III clinical trials. Longer analyses are required to further establish the safety profile of abrocitinib.https://www.tandfonline.com/doi/10.1080/09546634.2024.2411855Abrocitinibatopic dermatitisJAK inhibitors |
| spellingShingle | Luigi Gargiulo Luciano Ibba Angela Alfano Piergiorgio Malagoli Fabrizio Amoruso Anna Balato Francesca Barei Anna G. Burroni Stefano Caccavale Piergiacomo Calzavara-Pinton Maria Esposito Maria C. Fargnoli Silvia M. Ferrucci Caterina Foti Giampiero Girolomoni Massimo Gola Mario B. Guanti Carlotta Gurioli Manfredi Magliulo Martina Maurelli Pietro Morrone Maria L. Musumeci Maddalena Napolitano Michela Ortoncelli Cataldo Patruno Bianca M. Piraccini Elena Pezzolo Simone Ribero Mariateresa Rossi Paola Savoia Claudio Sciarrone Benedetta Tirone Marco Vaccino Federica Veronese Antonio Costanzo Alessandra Narcisi Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) Journal of Dermatological Treatment Abrocitinib atopic dermatitis JAK inhibitors |
| title | Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) |
| title_full | Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) |
| title_fullStr | Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) |
| title_full_unstemmed | Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) |
| title_short | Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis) |
| title_sort | short term effectiveness and safety of abrocitinib in adults with moderate to severe atopic dermatitis results from a 16 week real world multicenter retrospective study il ad italian landscape atopic dermatitis |
| topic | Abrocitinib atopic dermatitis JAK inhibitors |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2411855 |
| work_keys_str_mv | AT luigigargiulo shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT lucianoibba shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT angelaalfano shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT piergiorgiomalagoli shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT fabrizioamoruso shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT annabalato shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT francescabarei shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT annagburroni shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT stefanocaccavale shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT piergiacomocalzavarapinton shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT mariaesposito shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT mariacfargnoli shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT silviamferrucci shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT caterinafoti shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT giampierogirolomoni shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT massimogola shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT mariobguanti shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT carlottagurioli shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT manfredimagliulo shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT martinamaurelli shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT pietromorrone shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT marialmusumeci shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT maddalenanapolitano shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT michelaortoncelli shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT cataldopatruno shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT biancampiraccini shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT elenapezzolo shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT simoneribero shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT mariateresarossi shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT paolasavoia shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT claudiosciarrone shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT benedettatirone shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT marcovaccino shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT federicaveronese shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT antoniocostanzo shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis AT alessandranarcisi shorttermeffectivenessandsafetyofabrocitinibinadultswithmoderatetosevereatopicdermatitisresultsfroma16weekrealworldmulticenterretrospectivestudyiladitalianlandscapeatopicdermatitis |